Related Experiment Video

Updated: Aug 17, 2026

Pre-clinical Model of Cardiac Donation after Circulatory Death
06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

Aspartate and glutamate-enriched cardioplegia in left ventricular dysfunction

Ibrahim Uyar1, Denyan Mansuroğlu, Kaan Kirali

  • 1Department of Cardiovascular Surgery, Koşuyolu Heart and Research Hospital, Istanbul, Turkey.

Journal of Cardiac Surgery
|June 30, 2005
PubMed

Insights

L-aspartate and L-glutamate cardioplegia did not improve left ventricular function after bypass surgery in patients with moderate dysfunction. This study found no significant difference in recovery or myocardial enzyme levels between groups.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Cardioplegia Research

Background:

  • Investigating the impact of L-aspartate and L-glutamate-enriched cardioplegia on cardiac function.
  • Focusing on patients with moderate left ventricular dysfunction (LVEF 30-40%) undergoing coronary artery bypass surgery.

Purpose of the Study:

  • To evaluate the efficacy of L-aspartate and L-glutamate in improving postoperative left ventricular function.
  • Comparing outcomes between a substrate-enriched cardioplegia group and a standard cardioplegia group.

Main Methods:

  • Prospective randomized study of 22 patients with moderate left ventricular dysfunction.
  • Comparison of isothermic substrate-enriched (L-aspartate and L-glutamate) blood cardioplegia versus standard potassium-based cardioplegia.
  • Monitoring of hemodynamic parameters, perfusion time, aortic cross-clamp time, and cardioplegic solution volume.

Main Results:

  • No significant differences in intra- or postoperative periods between groups.
  • Similar myocardial acidosis and lactate levels despite more severe acidosis in the control group.
  • Higher Troponin-T levels observed in the control group, indicating potential myocardial damage.

Conclusions:

  • L-aspartate and L-glutamate may support myocardial metabolic functions.
  • These amino acids did not demonstrate a significant effect on myocardial functional recovery in this patient cohort.
  • Further research may be needed to explore their role in specific cardiac conditions.
Abstract

More Related Videos

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest08:30

Murine Isolated Heart Model of Myocardial Stunning Associated with Cardioplegic Arrest

Published on: August 6, 2015

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...